Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Plus Therapeutics Inc (PSTV)

NASDAQ
Currency in USD
Disclaimer
1.660
+0.060(+3.75%)
Closed

PSTV Comments

According to analysts, PSTV stock is rated as a "Strong Buy." The average 12-month stock price forecast is $10.00, representing a substantial increase of over 525% from the current price​​​​​​. Innovative Drug Development: Plus Therapeutics focuses on developing treatments for cancer and other diseases. Their lead drug candidate, Rhenium-186Re obisbemeda, targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. They are also working on other promising treatments for solid organ cancers​​. FDA Orphan Drug Designation: The company recently received U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the treatment of breast cancer with leptomeningeal metastases. This designation can provide certain benefits, including market exclusivity upon approval, assistance in clinical study design, tax credits, and exemption from FDA user fees​​. Share Repurchase Program: Plus Therapeutics announced a share repurchase program, indicating confidence in their financial stability and future prospects​​. Clinical Trial Progress: The company has been making progress in its clinical trials. For instance, they completed dosing in Cohort 4 of the ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases and plan to move into the next cohort following safety reviews​​​​.
Can we file a case against all these analysts who hv giving fake hopes
wondering if it hits 2+
Zero sales but everyone says strong buy - always confused with this Co but stuck n feels like slow quiksand
Like others they are expecting discovery of a candidate and then boom It happens but rare
My thoughts also
Its a very strong buy
I guess its an even stronger buy today
Its merging from the ashes now.
Really what happened????
$PSTV Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public OfferingThe Series U Warrants have an exercise price of $5.00 per share
This stupid firm offered millions of share mid-day at 5$ while stock was still trading at 10$. It just took few seconds to drop to 4$. It was unfair of them to do offering at 5$ as lots of bulls got trapped within seconds.
After 8 yesterday, first 16, then 3,56 today? What's going on here?
1:50
anyone holding the cytori warrants and know how it will be converted - same 50:1 ?
This stock has a strong buy technical analysis and it should. Has the potential of quadrupole gains. Bought at 0.33 and looking to make thousands off this when it hits over a 1.00.
you missed on this. reverse split in a couple of weeks
I don't think so.
8 year was 118 now is 0.4
not true..they did two reverse splits
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.